Overview

A class action lawsuit has been filed against PomDoctor, Ltd. (“PomDoctor” or the “Company”) (NASDAQ : POM) and certain of the Company’s senior executive officers, underwriter, independent auditor, and agent for service of process (collectively, “Defendants”) alleging violations of the federal securities laws. The PomDoctor lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired PomDoctor securities between October 9, 2025, and December 11, 2025, inclusive (the “Class Period”). Investors have until April 6, 2026, to seek appointment as lead plaintiff of the PomDoctor class action lawsuit.

PomDoctor claims to be an online medical services platform for chronic diseases in China.

The PomDoctor lawsuit arises from the crash of the Company’s stock in December 2025, following a dramatic yet illusory run-up orchestrated by a fraudulent stock promotion scheme. The Class Period begins on October 9, 2025, when the Company filed a prospectus containing false and misleading statements about PomDoctor’s financial well-being and prospects to facilitate the Company’s initial public offering (“IPO”).  

In the weeks leading up to December 10, 2025, PomDoctor’s share price surged from the IPO price of $4.00 per share to an all-time high of $6.09 per share, despite no fundamental news from the Company justifying such an increase. Investigations and public reports have since revealed that PomDoctor utilized social media to orchestrate an illicit “pump and dump” scheme to defraud investors. The reports detail how impersonators claiming to be legitimate financial advisors touted PomDoctor in online forums, chat groups, and through social media posts with sensational but baseless claims to induce investors to purchase PomDoctor shares. 

The complaint further alleges the structure of PomDoctor’s IPO was intentionally designed to facilitate an eventual pump and dump scheme. PomDoctor conducted a low-float IPO, offering just 833,334 shares to the public, merely 4% of total outstanding equity, while maintaining overwhelming insider control through Class B super-voting shares and offshore holding entities.

On December 10, 2025, PomDoctor’s stock price suddenly crashed by approximately 91%, closing at $0.50 per share. The Company’s stock price has not recovered, hovering around $0.22 per share at the time the lawsuit was filed. 

*          *          *

If you purchased or otherwise acquired PomDoctor securities between October 9, 2025, and December 11, 2025, and you wish to serve as lead plaintiff in this lawsuit, you are encouraged to submit your information to DiCello Levitt LLP via the form on this page.

You can also contact DiCello Levitt attorneys Brian O’Mara and Hani Farah by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as a lead plaintiff in the PomDoctor class action lawsuit is April 6, 2026.